Tradestie Institutional Equity Comparison Engine

MRVI vs SKIN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SKIN Overall Edge

SKIN Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to The Beauty Health Company Class A Common Stock (SKIN) driven by superior Valuation, Growth & Margin, Momentum & Technical while MRVI counters with relative strength in Options & Structure. Fundamentally, MRVI trades at N/M Forward P/E with -24.2% operating margin (+10.1% YoY revenue) versus SKIN at 106.4x Forward P/E and 2.4% operating margin (-2.1% YoY). In options structure, MRVI sits in BREAKOUT (35th %ile IV; Dealer Gamma Walls on Pro) against SKIN sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner SKIN
MRVI N/M vs SKIN 106.4x Fwd P/E
Growth & Margin Winner SKIN
Op Margin -24.2% vs 2.4% ยท YoY +10.1% vs -2.1%
Momentum & Technical Winner SKIN
1Y +127.7% vs +1057.7% ยท 52W Pos 70% vs 83%
Options & Structure Winner MRVI
BREAKOUT (35th %ile IV) vs UNCLASSIFIED (100th %ile IV)
MRVI NASDAQ
Maravai LifeSciences Holdings, Inc. Class A Common Stock
Pharmaceutical Preparations
$7.40
-1.86% 1D
Market Cap $2.0B
1M Return +8.98%
1Y Return +127.69%
Forward P/E N/M
Unified AI Score
52.0 / 100 HOLD
Tech 37.0 Fund 53.0 Flow 67.0 Mom 64.0
SKIN NASDAQ
The Beauty Health Company Class A Common Stock
Surgical & Medical Instruments & Apparatus
$15.05
-7.73% 1D
Market Cap $106.3M
1M Return +42.52%
1Y Return +1057.69%
Forward P/E 106.4x
Unified AI Score
34.1 / 100 SELL
Tech 50.0 Fund 34.0 Flow 67.0 Mom 46.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MRVI +127.69% SKIN +1057.69% Spread: +930.0 pp (SKIN Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period MRVI Revenue SKIN Revenue MRVI Op. Margin SKIN Op. Margin Margin Edge
FY2019 $140M $170M 16.8% 8.1% MRVI
FY2020 $280M $120M 42.2% -14.4% MRVI
FY2021 $800M $260M 69.4% -15.4% MRVI
FY2022 $880M $370M 65.0% -7.1% MRVI
FY2023 $290M $400M -11.0% -32.9% MRVI
FY2024 $260M $330M -90.9% -20.3% SKIN
FY2025 $190M $300M -115.9% -6.9% SKIN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MRVI (5) vs SKIN (5)
Institutional Metric MRVI SKIN Criterion Row Winner
Market Capitalization Scale $2.0B $106.3M Larger Scale MRVI
Trailing P/E Ratio Valuation N/M 106.4x Lower Multiple SKIN
Forward P/E Ratio Valuation N/M 106.4x Lower Multiple SKIN
Revenue Growth (YoY) Growth +10.1% -2.1% Higher Growth MRVI
Operating Margin (TTM) Profitability -24.2% 2.4% Higher Margin SKIN
Net Profit Margin Profitability -30.8% -6.3% Higher Margin SKIN
Return on Equity (ROE) Capital Efficiency -29.8% -30.1% Higher ROE MRVI
52-Week Range Position Momentum 70% ($3โ€“$9) 83% ($0โ€“$18) Stronger Trend SKIN
Beta / 30D Volatility Risk Regime 1.61ฮฒ ยท 83% Vol -14.22ฮฒ ยท 192% Vol Lower Realized Risk MRVI
Unified Institutional Score Composite Signal 52.0 / 100 (HOLD) 34.1 / 100 (SELL) Higher Composite MRVI

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MRVI vs SKIN Buy Guide
MRVI BREAKOUT
98d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 35th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MRVI Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SKIN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live SKIN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MRVI nor SKIN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.